ChiCTR‐IIR‐17013377.

Study name	Efffect of ivabradine in heart failure with preserved ejection fraction: a multicenter and randomized controlled clinical trial
Methods	Study design: Multicentre randomised controlled clinical trial (parallel) Unit of randomisation: Random sequence generated by SPSS software (19.0) Total duration of study: 31 December 2017 to 30 April 2018 Intervention time: No information Follow‐up: No information Setting: Department of Cardiology, The First Affiliated Hospital, Sun Yat‐sen University
Participants	Type of heart failure: HF‐PEF N = 60 participants (30 intervention; 30 placebo) Age: 18 to 70 years Gender: Both males and females Inclusion criteria: Aged 18~70 years With a history of symptomatic chronic heart failure of at least 3 months (NYHA class II or III), to receive the optimal treatment and to be in a stable clinical condition EF% ≥ 50% At least 1 predefined echocardiographic criterion related to diastolic dysfunction as evaluated by the investigating site: echo‐Doppler E/e' ratio of > 13; e' lateral < 10 cm/s and e′ septal < 8 cm/s; indexed volume of the left atrium (LAVI) of > 34 mL/m2 E/e' = ratio of peak early diastolic mitral flow velocity divided by the mean of the annular lateral (e′ lateral) and septal (e′ septal) velocities. Patient enrolment were exercise capacity < 80% of age‐predicted and sex‐predicted normal ranges in Cardiopulmonary Exercise Testing. Exclusion criteria: 1. Severe valvular disease, primary hypertrophic or restrictive cardiomyopathy, and systemic illness associated with infiltrative heart disease 2. Permanent atrial fibrillation or recent (< 3 months) atrial fibrillation‐related hospitalisation, pacemaker carriage 3. Severe or uncontrolled hypertension (systolic blood pressure > 160 mmHg or diastolic blood pressure > 100 mmHg) 4. Treatments not allowed at inclusion and during the study included non‐dihydropyridine calcium channel blockers, class I antiarrhythmics, and strong inhibitors of cytochrome P450 3A4 5. Heart rate < 60 beats/min; sick sinus syndrome; second‐ and third‐degree atrioventricular block 6. Established or suspected pulmonary diseases, sever joint‐associated disease, COPD, pulmonary hypertension 7. ACS in recent 2 months or coronary revascularisation in recent 6 months
Interventions	Intervention: Ivabradine Comparison: Placebo Concomitant medications: No information Excluded medications: Non‐dihydropyridine calcium channel blockers, class I antiarrhythmics, and strong inhibitors of cytochrome P450 3A4
Outcomes	Outcomes and time points measured in the study: [1, 4 weeks] Primary outcome: VO2 peak Measure method: Cardiopulmonary Exercise Testing
Starting date	31 December 2017
Contact information	Cao Yalin Department of Cardiology, The First Affiliated Hospital, Sun Yat‐sen University 58 Second Zhongshan Road Yuexiu District Guangzhou, Guangdong China Phone: +86 13650917403 Email: 1132909739@qq.com
Notes	Primary sponsor: The First Affiliated Hospital of Sun Yat‐sen University Secondary sponsor: Nanfang Hospital, Southern Medical University Military General Hospital of Guangzhou The First People's Hospital of Guangzhou Ethics status: Approved by ICE for clinical research and animal trials of the First Affiliated Hospital of Sun Yat‐sen University